An Essential Primer for Understanding the Role of Topical Hemostats, Surgical Sealants, and Adhesives for Maintaining Hemostasis

被引:64
作者
Gabay, Michael [1 ]
Boucher, Bradley A. [2 ]
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
[2] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Clin Pharm, Memphis, TN 38163 USA
来源
PHARMACOTHERAPY | 2013年 / 33卷 / 09期
关键词
topical hemostat; sealant; surgical bleeding; hemostasis; thrombin; gelatin; pharmacist's role; pharmacy and therapeutics committee; OXIDIZED CELLULOSE SURGICEL(R); RANDOMIZED CLINICAL-TRIAL; FIBRIN SEALANT; ACHIEVING HEMOSTASIS; GRANULOMA MIMICKING; BLOOD-TRANSFUSIONS; POLYMERIC SEALANT; TISSUE ADHESIVES; THROMBIN; MATRIX;
D O I
10.1002/phar.1291
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A wide variety of topical hemostats are approved as adjunctive therapies in the maintenance of hemostasis during surgical procedures in which conventional methods are insufficient or not practical. A multidisciplinary approach to the selection and application of these agents requires input from all members of the surgical team including surgeons, perioperative nurses, blood bank specialists, and pharmacists. However, pharmacist knowledge regarding topical hemostats may be limited based on lack of formal education within college of pharmacy curricula as well as their use being predominantly in the operating room setting. Furthermore, some of these agents might be procured through central supply rather than the hospital pharmacy. Topical hemostats include agents that act as a mechanical barrier to bleeding and provide a physical matrix for clotting, biologically active agents that catalyze coagulation, combination therapies, and synthetic sealants and adhesives. Although many of the topical hemostats were approved for use before the requirement for clinical trials, this review provides an overview of the available clinical evidence regarding the appropriate uses and safety considerations associated with these agents. Proper use of these agents is vital to achieving the best clinical outcomes. Specifically, knowledge of the contraindications and potential adverse events associated with topical hemostats can help prevent unwanted outcomes. Therefore, an understanding of the benefits and potential risks associated with these agents will allow hospital pharmacists to assist in the development and implementation of institutional policies regarding the safe and effective use of hemostatic agents commonly used in the surgical suite.
引用
收藏
页码:935 / 955
页数:21
相关论文
共 107 条
[11]  
Baxter Healthcare Corp, 2005, FLOSEAL HEM MATR
[12]  
Baxter Healthcare Corp, 2009, GELF ABS GEL SPONG U
[13]  
Baxter Healthcare Corp, 2009, COAS SURG SEAL INSTR
[14]  
Baxter Healthcare Corp, 2010, TACHOSIL ABS FIBR SE
[15]  
Baxter Healthcare Corp, 2010, TISS TM FIBR SEAL FR
[16]  
Baxter Healthcare Corp, TACHOSIL ABS FIBR SE
[17]  
Bhende Shubhangi, 2002, Surg Infect (Larchmt), V3, P251, DOI 10.1089/109629602761624216
[18]   Achieving Hemostasis in the Surgical Field [J].
Boucher, Bradley A. ;
Traub, Oren .
PHARMACOTHERAPY, 2009, 29 (07) :2S-7S
[19]  
Brodbelt AR, 2002, ANN ROY COLL SURG, V84, P97
[20]  
Centers for Medicare & Medicaid Services Conditions of Participation, STAT OP MAN APP A SU